Skip to main content

Kyowa Hakko Kirin Value Stock - Dividend - Research Selection

Kyowa Hakko Kirin Co., Ltd.

ISIN: JP3256000005, WKN: 858523

Market price date: 19.07.2021
Market price: 3.785,00 JPY




Kyowa Hakko Kirin Co., Ltd. Fundamental data and company key figures of the share

Annual reports in JPY
Key figures 18-02-2021
Cash flow
Net operating cash flow 39.502.000.000
Capital Expenditures -35.227.000.000
Free cash flow 4.275.000.064
Balance sheet
Total Equity 698.396.000.000
Liabilities & Shareholders equity 801.290.000.000
Income statement
Net income 47.027.000.000
Eps (diluted) 87,500
Diluted shares outstanding 537.000.000
Net sales/revenue 318.352.000.000

Fundamental ratios calculated on: 19-07-2021

Ratios
Key figures 19-07-2021
Cash flow
P/C 51,45
   
P/FC 475,45
Balance sheet
ROI5,87
ROE87,16
Income statement
P/E43,26
Div. Yield0,00%
P/B2,91
P/S6,39


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol4151.TSE
Market Capitalization19.596.083.200,00 USD
Country
IndicesNIKKEI 225
Sectors
Raw Data SourceIFRS in Millionen JPY
Stock Split
Internetwww.kyowa-kirin.co.jp


Description of the company

Kyowa Hakko Kirin Co., Ltd. is mainly engaged in medical product and Biochemical businesses. The Medical Product segment is engaged in the manufacture, sale and sales promotion of ethical drug and reagent for clinical test, the development of candidate substances for new drugs, as well as the research and development of technologies for antibody drug creation, among others. It also involved in the contracting, retail and wholesale, and insurance agency businesses. The Biochemical segment manufactures and sells medical and industrial materials, mainly amino and nucleic acids, and healthcare products. This segment also designs and constructs facilities. As of December 31, 2013, it had 47 subsidiaries, three associated companies and one parent company.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.kyowa-kirin.co.jp